Mayoral candidate Scott Stringer is proposing a new zoning designation to block President Donald Trump from auctioning off federal buildings to luxury developers, the Daily News has ...

Bayer will present new data from the ARANOTE trial evaluating ultra-low prostate-specific antigen responses with NUBEQA ® ...

Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Global ...

In the PSMAfore trial, Pluvicto reduced the risk of radiographic progression or death by 59%. The Food and Drug Administration (FDA) has expanded the approval of Pluvicto ® (lutetium Lu 177 ...

The addition of a short-course of ADT to metastasis-directed therapy delays progression in patients with oligometastatic hormone-sensitive prostate cancer. Adding 6 months of androgen deprivation ...

The study is expected to enroll approximately 203 patients with mCRPC who have progressed despite prior therapy and have been treated with at least one anti-androgen therapy (enzalutamide, apalutamide ...

The ARANOTE, PEACE-3, and SPLASH trials showcased new treatment options in advanced prostate cancer. ARANOTE confirmed darolutamide + ADT improves rPFS in mHSPC, while PEACE-3 demonstrated that ...